RU2014135436A - Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака - Google Patents
Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака Download PDFInfo
- Publication number
- RU2014135436A RU2014135436A RU2014135436A RU2014135436A RU2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A RU 2014135436 A RU2014135436 A RU 2014135436A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- groups
- unsubstituted
- group
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593047P | 2012-01-31 | 2012-01-31 | |
| US61/593,047 | 2012-01-31 | ||
| PCT/US2013/023781 WO2013116293A1 (en) | 2012-01-31 | 2013-01-30 | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014135436A true RU2014135436A (ru) | 2016-03-27 |
Family
ID=47679114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014135436A RU2014135436A (ru) | 2012-01-31 | 2013-01-30 | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140378422A1 (2) |
| EP (1) | EP2809312A1 (2) |
| JP (1) | JP2015505562A (2) |
| KR (1) | KR20140117457A (2) |
| CN (1) | CN104093402A (2) |
| AU (1) | AU2013215251A1 (2) |
| BR (1) | BR112014017985A8 (2) |
| CA (1) | CA2861377A1 (2) |
| IN (1) | IN2014DN05869A (2) |
| MX (1) | MX2014009303A (2) |
| RU (1) | RU2014135436A (2) |
| WO (1) | WO2013116293A1 (2) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015136016A2 (en) * | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| LT3386500T (lt) | 2015-12-09 | 2022-12-27 | The Board Of Trustees Of The University Of Illinois | Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| MA51570A (fr) * | 2018-01-10 | 2020-11-18 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du carcinome hépatocellulaire |
| JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
| TWI841598B (zh) * | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| WO2020110974A1 (ja) * | 2018-11-26 | 2020-06-04 | 大鵬薬品工業株式会社 | 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法 |
| AU2021315234A1 (en) * | 2020-07-31 | 2023-01-19 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
| CN116940363A (zh) * | 2021-03-03 | 2023-10-24 | 正大天晴药业集团股份有限公司 | Cdk4/6抑制剂的联用药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (2) | 1962-09-13 | |||
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| DE60115069T2 (de) | 2000-09-11 | 2006-08-03 | Chiron Corp., Emeryville | Chinolinonderivate als tyrosin-kinase inhibitoren |
| US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| ITTV20030095A1 (it) | 2003-07-14 | 2005-01-15 | Asolo Spa | Calzatura con sottopiede composito. |
| US20050209247A1 (en) | 2003-11-07 | 2005-09-22 | Chiron Corporation | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| EP2301546B1 (en) * | 2005-01-27 | 2014-09-10 | Novartis AG | Treatment of metastasized tumors |
| EP1885187B1 (en) * | 2005-05-13 | 2013-09-25 | Novartis AG | Methods for treating drug resistant cancer |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| NZ567550A (en) | 2005-11-29 | 2011-08-26 | Novartis Ag | Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
-
2013
- 2013-01-30 EP EP13703295.9A patent/EP2809312A1/en not_active Withdrawn
- 2013-01-30 MX MX2014009303A patent/MX2014009303A/es unknown
- 2013-01-30 AU AU2013215251A patent/AU2013215251A1/en not_active Abandoned
- 2013-01-30 KR KR1020147021140A patent/KR20140117457A/ko not_active Ceased
- 2013-01-30 CN CN201380006947.7A patent/CN104093402A/zh active Pending
- 2013-01-30 US US14/375,145 patent/US20140378422A1/en not_active Abandoned
- 2013-01-30 WO PCT/US2013/023781 patent/WO2013116293A1/en not_active Ceased
- 2013-01-30 CA CA2861377A patent/CA2861377A1/en not_active Abandoned
- 2013-01-30 BR BR112014017985A patent/BR112014017985A8/pt not_active Application Discontinuation
- 2013-01-30 RU RU2014135436A patent/RU2014135436A/ru unknown
- 2013-01-30 JP JP2014555661A patent/JP2015505562A/ja active Pending
- 2013-01-30 IN IN5869DEN2014 patent/IN2014DN05869A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014017985A2 (2) | 2017-06-20 |
| MX2014009303A (es) | 2014-10-14 |
| AU2013215251A1 (en) | 2014-08-14 |
| WO2013116293A1 (en) | 2013-08-08 |
| IN2014DN05869A (2) | 2015-05-22 |
| EP2809312A1 (en) | 2014-12-10 |
| US20140378422A1 (en) | 2014-12-25 |
| JP2015505562A (ja) | 2015-02-23 |
| BR112014017985A8 (pt) | 2017-07-11 |
| KR20140117457A (ko) | 2014-10-07 |
| CN104093402A (zh) | 2014-10-08 |
| CA2861377A1 (en) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| RU2018106453A (ru) | Соединения | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| RU2016134751A (ru) | Соединения | |
| JP2019510832A5 (2) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| JP2014505735A5 (2) | ||
| JP2013528600A5 (2) | ||
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| MX372814B (es) | Dihidronaftiridinas y compuestos relacionados útiles como inhibidores cinasas para el tratamiento de enfermedades proliferativas. | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| JP2013507415A5 (2) | ||
| RU2013155586A (ru) | [1,3]оксазины | |
| SI2953948T1 (en) | Fluorinated integrin antagonists | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2015535247A5 (2) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2016522254A5 (2) | ||
| JP2015522033A5 (2) | ||
| RU2012135698A (ru) | Способ и композиция | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 |